<b>Conclusions:</b> Our study demonstrated that the ARGs could serve as a novel biomarker for predicting the prognosis of patients with HER2-positive breast cancer and providing new insights into immunotherapy strategies for these patients. This evidence concerns the gene ERBB2 and breast cancer.